<DOC>
	<DOCNO>NCT01163487</DOCNO>
	<brief_summary>The purpose study study effect drug DCA ( dichloroacetate ) recurrent head neck cancer . Part study also use EF5 PET scan study tumor hypoxia .</brief_summary>
	<brief_title>Phase I Trial Metabolic Reprogramming Therapy Treatment Recurrent Head Neck Cancers</brief_title>
	<detailed_description />
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<criteria>Pathologically confirm head neck squamous cell carcinoma Age &gt; 18 year old Patients must unresectable disease accept potentially curative treatment option Patients must acceptable organ marrow function define : leukocyte &gt; 3,000/uL absolute neutrophil count &gt; 1,500/uL platelet &gt; 90,000/uL total bilirubin &lt; =1.5X normal institutional limit AST ( SGOT ) /ALT ( SGPT ) &lt; =2.5 X normal institutional limit follow exception : 1 . Patients document tumor involve liver Grade &lt; 2 elevation AST , ALT , and/or alkaline phosphatase eligible &lt; 5X ULN . 2 . Patients document tumor involve bone Grade &lt; 2 elevation alkaline phosphatase eligible &lt; 5X ULN . creatinine &lt; =1.5X normal institutional limit OR creatinine clearance &gt; 50 mL/min basis CockcroftGault glomerular filtration rate estimation Patients must noncranial gross disease great 1 cm CT scan prior enrollment Disease must FDGavid PET scan Creatinine within normal institutional limit Eastern Clinical Oncology Group performance status 0 , 1 2 ( Appendix 1 ) Life expectancy &gt; 12 week Both men woman member race ethnic group eligible trial . Women pregnant Administration systemic cytotoxic agent within last 2 week enrollment Patients unwilling unable provide inform consent Patients potentially curable disease Participation another concurrent treatment protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>